Two months after the last chemotherapy, Bianca Balti resumes her battle against cancer. Fresh from participating in the Milan ...
Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...
New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...
Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...
News Medical on MSN6d
Genomic study reveals important similarities and differences in ovarian cancer mutations across populationsGenomic analyses funded by the National Cancer Institute show that ovarian cancer mutations are nearly identical across ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback